Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
Completed · Phase 1
Conditions studied: Healthy
In brief
This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow the 25 mg IV dose.
Key facts
- Study ID
- NCT00447681
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 56
- Starts
- 2006-12-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2007-12-13
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.